XML 23 R5.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2022 $ 41,000 $ 121,081,000 $ (98,075,000) $ 23,047,000
Balance, shares at Dec. 31, 2022 40,518,792      
Stock-based compensation - Lucid Diagnostics Inc. 2018 Equity Plan 5,762,000 5,762,000
Stock-based compensation - PAVmed Inc. 2014 Equity Plan 1,060,000 1,060,000
Vest - restricted stock awards
Vest - restricted stock awards, shares   303,980      
Conversions - Senior Secured Convertible Note 166,000 166,000
Conversions - Senior Secured Convertible Note, shares   115,388      
Issuance common stock - APA-RDx - Termination payment 713,000 713,000
Issuance common stock - APA-RDx - Termination payment, shares   553,436      
Issuance - At-The-Market Facility, net of financing charges $ 1,000 283,000 284,000
Issuance - At-The-Market Facility, net of financing charges, shares   230,068      
Purchase - Employee Stock Purchase Plan 551,000 551,000
Purchase - Employee Stock Purchase Plan, shares   508,200      
Issuance - Series A and Series A-1 Preferred Stock 18,625,000 18,625,000
Issuance - Series A and Series A-1 Preferred Stock, shares 18,625        
Issue common stock - vendor service agreement 147,000 147,000
Issue common stock - vendor service agreement, shares   100,000      
Net loss (52,666,000) $ (52,666,000)
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan, shares        
Balance at Dec. 31, 2023 $ 18,625,000 $ 42,000 129,763,000 (150,741,000) $ (2,311,000)
Balance, shares at Dec. 31, 2023 18,625 42,329,864      
Stock-based compensation - Lucid Diagnostics Inc. 2018 Equity Plan 4,183,000 4,183,000
Stock-based compensation - PAVmed Inc. 2014 Equity Plan 351,000 351,000
Vest - restricted stock awards
Vest - restricted stock awards, shares   26,912      
Conversions - Senior Secured Convertible Note $ 14,000 13,468,000 13,482,000
Conversions - Senior Secured Convertible Note, shares   13,866,867      
Purchase - Employee Stock Purchase Plan $ 1,000 446,000 447,000
Purchase - Employee Stock Purchase Plan, shares   647,940      
Issue common stock - vendor service agreement $ 1,000 640,000 $ 641,000
Issue common stock - vendor service agreement, shares   790,000     790,000
Net loss (45,529,000) $ (45,529,000)
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan 4,000 $ 4,000
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan, shares   3,333     3,333
Issuance - Series A-1 Preferred Stock $ 5,670,000 $ 5,670,000
Issuance - Series A-1 Preferred Stock, shares 5,670        
Exchange - Series A and Series A-1 Preferred Stock $ (24,295,000) (7,496,000) (31,791,000)
Exchange - Series A and Series A-1 Preferred Stock, shares (24,295)        
Issuance through exchange - Series B and Series B-1 Preferred Stock $ 31,790,000 31,790,000
Issuance through exchange - Series B and Series B-1 Preferred Stock, shares 31,790        
Issuance through sale- Series B and Series B-1 Preferred Stock $ 24,129,000 24,129,000
Issuance through sale- Series B and Series B-1 Preferred Stock, shares 24,129        
Conversions - Series B Preferred Stock $ (1,500,000) $ 2,000 1,498,000
Conversions - Series B Preferred Stock, shares (1,500) 2,075,263      
Issuance - Due To: PAVmed Inc. Settlement in Common Stock $ 3,000 4,672,000 4,675,000
Issuance - Due To: PAVmed Inc. Settlement in Common Stock, shares   3,331,771      
Transfer of intellectual property from PAVmed Inc. (350,000) (350,000)
Balance at Dec. 31, 2024 $ 54,419,000 $ 63,000 $ 154,675,000 $ (203,766,000) $ 5,391,000
Balance, shares at Dec. 31, 2024 54,419 63,071,950